Barclays Starts Idenix Pharmaceuticals (IDIX) at Equalweight
IDIX Hot Sheet
Rating Summary:5 Buy, 5 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Barclays initiates coverage on Idenix Pharmaceuticals (NASDAQ: IDIX) with a Equalweight. PT $10.00.
For an analyst ratings summary and ratings history on Idenix Pharmaceuticals click here. For more ratings news on Idenix Pharmaceuticals click here.
Shares of Idenix Pharmaceuticals closed at $11.13 yesterday, with a 52 week range of $2.67-$15.25.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
For an analyst ratings summary and ratings history on Idenix Pharmaceuticals click here. For more ratings news on Idenix Pharmaceuticals click here.
Shares of Idenix Pharmaceuticals closed at $11.13 yesterday, with a 52 week range of $2.67-$15.25.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- UPDATE: William Blair Starts EPIQ Systems (EPIQ) at Outperform; Broad Suite of Solutions in Electronic Discovery Sector
- Brean Murray Sees Recent Upside in Idenix (IDIX) Related to Possible Gilead (GILD) Settlement in June
- Needham & Company Reiterates a 'Buy' on UQM Technologies (UQM); Increasing EV Adoption
Create E-mail Alert Related Categories
New CoverageRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
